Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase I study of oral spirogermanium

Summary

Thirty-three patients with advanced malignancy were treated with oral spirogermanium in a Phase I study to determine a maximum tolerated dose. Patients were entered in the study at doses of 100, 200, and 300 milligrams daily. The dose-limiting toxicity was gastrointestinal with moderate nausea and vomiting occurring with the 300 milligram dose. No myelosuppression or renal dysfunction was noted. Elevations of serum transaminase were seen in 41 percent of the patients at study entry. While abnormalities in hepatic function were recorded during the study, the relationship to spirogermanium could not be determined. No patient exhibited clinical hepatic dysfunction or elevation of serum bilirubin. It is recommended that future studies of oral spirogermanium incorporate careful monitoring of these parameters. Two patients with lymphoproliferative disorders had objective responses to therapy. A dose of 200 milligrams is recommended for further Phase II trials.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Rice LM, Wheeler JW, Geschickter GF: Spirans XXII. Synthesis of 4,4-dialkyl-4-germacyclohexanone and 8,8-dialkyl8-germaazaspiro [4.5] decanes. J of Heterocyclic Chem 11:1041–1047, 1974

  2. 2.

    Hill BT, Whatley SA, Bellamy AS, Jenkins LY, Whelan RDH: Cytotoxic effects and biological activity of 2-aza-8-germanspiro [4.5] -decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; Spirogermanium) in vitro. Cancer Res 42:2852–2856, 1982

  3. 3.

    Schein PS, Slavik M, Smythe T, Hoth D, Smith F, Macdonald JS, Woolley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051–1056, 1980

  4. 4.

    Espana P, Kaplan R, Robichaud K, Gustafson P, Wiernik P, Smith F, Woolley P, Schein P: Phase II study of spirogermanium in lymphoma patients. (Abstr) Proc Am Soc Clin Oncol 1:166, 1982

  5. 5.

    Woolley PV, Ahlgren JP, Byrne PJ, Priego VM, Schein PS: A Phase I trial of spirogermanium administered on a continuous infusion schedule. Invest New Drugs 2:302–306, 1984

Download references

Author information

Correspondence to Lucien Joubert.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Harvey, J., McFadden, M., Smith, F.P. et al. Phase I study of oral spirogermanium. Invest New Drugs 8, 53–56 (1990). https://doi.org/10.1007/BF00216924

Download citation

Key words

  • spirogermanium
  • phase I
  • oral